Literature DB >> 22594569

The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome.

Francesca Crovetto1, Nicolò Borsa, Barbara Acaia, Carla Nishimura, Kathy Frees, Richard J H Smith, Flora Peyvandi, Roberta Palla, Massimo Cugno, Silvana Tedeschi, Pierangela Castorina, Edgardo Somigliana, Gianluigi Ardissino, Luigi Fedele.   

Abstract

OBJECTIVE: Recent preliminary evidence suggests that gene mutations in the alternative pathway of complement may play a crucial role in the pathogenesis of HELLP syndrome. To verify this hypothesis, a consecutive series of women who developed the syndrome was screened for variants in alternative pathway genes.
METHODS: The coding sequences and intron-exon boundaries of the complement factor H (CFH), complement factor I (CFI), Membrane Cofactor Protein (MCP), complement factor B (CFB) and C3 were sequenced in 33 women with a diagnosis of HELLP syndrome.
RESULTS: Three patients carried heterozygotic variants - two in CFI and one in MCP. One of the two CFI mutations, was previously described as an unremarkable polymorphism. Conversely, computational analyses for the remaining two cases suggest that they may have a functional impact.
CONCLUSIONS: The present study confirms that the alternative pathway of complement may play a role in the pathogenesis of HELLP syndrome. However, its overall contribution to the determinism of the syndrome is less relevant than initially reported.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22594569     DOI: 10.3109/14767058.2012.694923

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  15 in total

1.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Kejian Zhang; Fanggeng Zou; Benjamin Laskin; Christopher E Dandoy; Kasiani C Myers; Adam Lane; Jaroslav Meller; Mario Medvedovic; Jenny Chen; Stella M Davies
Journal:  Blood       Date:  2015-11-24       Impact factor: 22.113

2.  Monitoring Complement Activation: The New Conundrum in Thrombotic Microangiopathies.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

Review 3.  Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy.

Authors:  Marie Scully
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

5.  Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome.

Authors:  Michelle Petri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 6.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

7.  Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.

Authors:  Arthur J Vaught; Evan M Braunstein; Jagar Jasem; Xuan Yuan; Igor Makhlin; Solange Eloundou; Andrea C Baines; Samuel A Merrill; Shruti Chaturvedi; Karin Blakemore; C John Sperati; Robert A Brodsky
Journal:  JCI Insight       Date:  2018-03-22

Review 8.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

Review 9.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

Review 10.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.